

STUDI ATTIVI AL RECLUTAMENTO S.C. OM1

<i>Prot. n°</i>			<i>Patologia</i>	<i>Titolo</i>	<i>osservazionale o sperimentale</i>	<i>profit / no profit</i>
220	/	19	NEUROENDOCRINO	ENETS - REGISTRY	O	NP
240	/	19	NET	Studio di fase II finalizzato a valutare il profilo di sicurezza e di attività di cabozantinib in combinazione a lanreotide in tumori neuroendocrini (NET) gastroenteropancreatici (GEP) e toracici (LOLA trial).	S	NP
299	/	20	NET	InterNaTional rEgistry oN Sars-cov-2 posltiVe nEuroendocrine neoplasm patients	O	NP
159	/	22	NET	Window-of-opportunity study of chemo-immunotherapy in patients with resectable Merkel Cell Carcinoma prior to surgery: the MERCURY trial	S	NP
130	/	20	NET	Identificazione di predittori molecolari di risposta alla terapia radiorecettoriale in pazienti con GEP-NETs	O	NP
177	/	14	PANCREAS-VIE BILIARI	Identificazione delle cellule tumorali circolanti e dei livelli di ctDNA nel sangue dei pazienti affetti	O	NP

STUDI ATTIVI AL RECLUTAMENTO S.C. OM1

72	/	19	PANCREAS-VIE BILIARI	“Studio multicentrico di Fase 3, in aperto, randomizzato, con controllo attivo per valutare l’efficacia e la sicurezza di pemigatinib rispetto a gemcitabina più chemioterapia a base di cisplatino nel trattamento di prima linea di partecipanti affetti da colangiocarcinoma non resecabile o metastatico con riarrangiamento di FGFR2 (FIGHT-302)”-	S	P
105	/	19	PANCREAS-VIE BILIARI	Studio Osservazionale sulla fattibilità e l’utilità’ di un’estesa caratterizzazione molecolare tramite Foundationone CDX in pazienti affetti da carcinomi biliopancreatici. NO PROFIT	O	NP
225	/	21	PANCREAS-VIE BILIARI	A randomized, double-blind, phase III study comparing NIS793 in combination with gemcitabine and nab-paclitaxel versus placebo combined with gemcitabine and nab-paclitaxel for first line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC)	S	P
113	/	21	PANCREAS-VIE BILIARI	STUDIO OSSERVAZIONALE SULL’IMPATTO PROGNOSTICO/PREDITTIVO DELLE ALTERAZIONI DEI GENI DEL DNA REPAIR SUI TUMORI BILIOPANCREATICI	O	NP
04	/	15	GASTRO-ENTERICO	Studio prospettico per la determinazione del profilo molecolare di resistenza alle “terapie target” in pazienti con tumori solidi – protocollo profiling-CANDIOLO	O	NP
117	/	15	GASTRO-ENTERICO	Valutazione esplorativa di nuovi potenziali fattori prognostici in pazienti affetti da carcinomi gastrointestinali	O	NP
120	/	15	GASTRO-ENTERICO	Studio multicentrico traslazionale per la determinazione del profilo genomico dei carcinomi a primitività sconosciuta (CUP). De braud	O	NP

STUDI ATTIVI AL RECLUTAMENTO S.C. OM1

103	/	16	GASTRO-ENTERICO	Assessment of Ramucirumab plus paclitaxel as switch MANTenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III Trial	S	NP
205	/	17	GASTRO-ENTERICO	Studio AMNESIA: Studio italiano osservazionale multicentrico sui meccanismi molecolari di resistenza al Trastuzumab in tumori dello stomaco o della giunzione gastro-esofagea (GGE) HER-2 positivi	O	NP
36	/	18	GASTRO-ENTERICO	ADJUVANT CAPECITABINE IN HIGH RISK PSEUDOMYXOMA PERITONEI PATIENTS TREATED WITH CYTOREDUCTIVE SURGERY (CRS) AND HYPERTERMIC INTRAPERITONEAL CHEMOTHERAPY (HIPEC)	S	NP
163	/	18	GASTRO-ENTERICO	NO PROFIT. Titolo PEMBROLIZUMAB IN PAZIENTI CON CANCRO DEL COLON RETTO METASTATICO CON SISTEMA DI "MISMATCH REPAIR" INTATTO DOPO INDUZIONE FARMACOLOGICA DI IPERMUTABILITÀ	S	NP
54	/	19	COLON	CLASSIFICAZIONE DEL RISCHIO DI RIPRESA DI MALATTIA ATTRAVERSO LO STUDIO DEL PROFILO METABOLOMICO E DEL DNA TUMORALE CIRCOLANTE (ctDNA) IN PAZIENTI CON TUMORI DEL COLON IN STADIO INIZIALE. no profit	O	NP

STUDI ATTIVI AL RECLUTAMENTO S.C. OM1

174	/	19	COLON	NO-PROFIT. A Phase III, Randomised, international trial comparing mFOLFIRINOX triplet chemotherapy to mFOLFOX for high-risk stage III colon cancer in adjuvant setting	S	NP
136	/	19	COLON	A master protocol empowering Precision Research in Colorectal Cancer. NO - PROFIT	O	NP
35	/	20	COLON	"A Randomized, Double-blind, Placebo-controlled Phase 3 Trial of Pembrolizumab (MK-3475) Versus Placebo in Participants with Esophageal Carcinoma Receiving Concurrent Definitive Chemoradiotherapy (KEYNOTE 975)."	S	P
204	/	20	ESOFAGO	RANDOMIZED PHASE II STUDY OF PANITUMUMAB RECHALLENGE FOLLOWED BY REGORAFENIB versus THE REVERSE SEQUENCE IN RAS AND BRAF WILD-TYPE CHEMOREFRACTORY METASTATIC COLORECTAL CANCER PATIENTS	S	NP
151	/	20	COLON	studio di Fase 1b con la combinazione 5-fluorouracile, leucovorin, irinotecano e temozolomide (FLIRT) in associazione a bevacizumab come trattamento di prima linea in pazienti con carcinoma del colon-retto metastatico con stabilità dei microsatelliti e silenziamento di MGMT	S	NP

STUDI ATTIVI AL RECLUTAMENTO S.C. OM1

289	/	20	COLON	A Phase 1b/2 Multicenter, Open-label, Dose-escalation and Doseexpansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of Trastuzumab Deruxtecan (T-DXd) Monotherapy and Combinations in Adult Participants with HER2-Overexpressing Gastric Cancer (DESTINY-Gastric03)	S	P
293	/	20	GASTRO-ENTERICO	Tremellmumab aNd durvalumab combination For the non-operative management (NOM) of Microsatellite Instability (MSI)-high resectable gastric or gastroesophageal junction cancer:The multicentre, single-arm, multi-cohort, Phase II INFINITY study.	S	NP
128	/	21	GASTRO-ENTERICO	A Phase 2, Multicenter, Multi Arm, Study to Evaluate Pembrolizumab (MK-3475) or MK-1308A (Co-formulated quavonlimab (MK-1308)/pembrolizumab) in Participants with Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer: (MK-1308A-008)	S	P
276	/	20	COLON	RETROSPECTIVE OBSERVATIONAL STUDY ON THE USE OF IMMUNOTHERAPY WITH ANTI PD-1 ANTIBODIES IN PATIENTS WITH MSI-H METASTATIC COLORECTAL CANCER - GOIRC-07-2019 (CA209-7TL)"	O	NP
125	/	21	COLON	"A Phase 3 Global, Multicenter, Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2)"	S	P

STUDI ATTIVI AL RECLUTAMENTO S.C. OM1

149	/	21	COLON	Studio di fase III randomizzato volto a valutare l'efficacia e la sicurezza di Lenvatinib (E7080/MK-7902) più Pembrolizumab (MK-3475) più chemioterapia rispetto alla terapia assistenziale standard come trattamento di prima linea nei partecipanti con adenocarcinoma gastroesofageo avanzato/metastatico (LEAP-015)	S	P
124	/	21	GASTRO-ENTERICO	Studio di fase 3, multicentrico, in aperto, randomizzato a due bracci di trastuzumab deruxtecan in soggetti con adenocarcinoma gastrico o della giunzione gastro-esofagea (GGE) HER2 positivo, metastatico e/o non resecabile che hanno manifestato una progressione durante o dopo un regime contenente trastuzumab (DESTINY-Gastric04)	S	P
65	/	21	GASTRO-ENTERICO	"Phase III study in mCRC patients with RAS/BRAF wild type tissue and RAS mutated in Liquid Biopsy to compare in first-line therapy FOLFIRI plus Cetuximab or Bevacizumab (LIBImAb Study)"	S	NP
188	/	21	COLON	"Multicenter phase II study of preoperative chemoradiotherapy with CApecitabine plus Temozolomide in patients with MGMT silenced and microsatellite stable locally Advanced RecTal Cancer: the CATARTIC trial"	S	NP
201	/	21	COLON	AN OPEN-LABEL, SINGLE-ARM, PHASE IB/IIA TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF THE EP4 RECEPTOR ANTAGONIST CR6086 IN COMBINATION WITH THE PD-1 INHIBITOR BALSTILIMAB (AGEN2034), IN PATIENTS WITH PRETREATED MISMATCH-REPAIR-PROFICIENT AND MICROSATELLITE STABLE METASTATIC COLORECTAL CANCER."	S	P

STUDI ATTIVI AL RECLUTAMENTO S.C. OM1

202	/	21	COLON	"A phase 1/2 study exploring the safety and activity of trifluridine/tipiracil in combination with capecitabine and bevacizumab in metastatic colorectal cancer patients"	S	P
173	/	21	COLON	Protocol Title:A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) + Lenvatinib (E7080/MK-7902) + Chemotherapy Compared with Standard of Care as First-line Intervention in Participants with Metastatic Esophageal Carcinoma	S	P
176	/	21	ESOFAGO	"Phase II study of Short-course radiotherapy followed by consolidation chemotherapy with the Triplet FOLFOXIRI as total neoadjuvant therapy for locally advanced rectal cancer: the ShorTrip study"	S	NP
216	/	21	COLON	Studio prospettico per l'investigazione della biologia tumorale e dei fattori di resistenza alle terapie mediante biopsia liquida e patient derived organoids (PDO) in pazienti con tumori del tratto gastroenterico, bilio-pancreatico, tumori neuroendocrini e carcinomi a cellule di Merkel"	O	NP
140	/	21	GASTRO-ENTERICO	ItaLynch: mainstreaming the diagnosis of Lynch Syndrome	O	NP

STUDI ATTIVI AL RECLUTAMENTO S.C. OM1

03	/	21	GASTRO-ENTERICO	Temozolomide and irinotecan consolidation in patients with MGMT silenced, microsatellite stable colorectal cancer with persistence of minimal residual disease in liquid biopsy after standard adjuvant chemotherapy: the ERASE-TMZ study	S	NP
38	/	22	COLON	"A Phase 3 Multicenter, Randomized, Open-label, Active-controlled Study of Sotorasib and Panitumumab Versus Investigator's Choice (Trifluridine and Tipiracil, or Regorafenib) for the Treatment of Previously Treated Metastatic Colorectal Cancer Subjects with KRAS p.G12C Mutation"	S	P
22	/	22	COLON	"A PHASE 2/3 STUDY OF ALX148 IN PATIENTS WITH ADVANCED HER2-OVEREXPRESSING GASTRIC/GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA (ASPEN-06)"	S	P
231	/	21	GASTRO-ENTERICO	Studio osservazionale sulle caratteristiche cliniche ed anatomopatologiche e sugli outcome dei pazienti affetti da carcinomi gastrointestinali e neoplasie neuroendocrine afferenti all'Istituto Nazionale dei Tumori di Milano.	O	NP
263	/	21	COLON	An open-label, multi-center, phase II platform study evaluating the efficacy and safety of NIS793 and other new investigational drug combinations with standard of care (SOC) anti-cancer therapy for the second line treatment of metastatic colorectal cancer (mCRC)	S	P

STUDI ATTIVI AL RECLUTAMENTO S.C. OM1

161	/	22	COLON	A Phase 3, Randomized, Open-label Study of Relatlimab-nivolumab Fixed-dose Combination Versus Regorafenib or Trifluridine + Tipiracil (TAS-102) for Participants with Later-lines of Metastatic Colorectal Cancer	S	P
156	/	22	GASTRO-ENTERICO	A Phase 1b/3 Study of Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab Alone in Subjects With Previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpression (FORTITUDE-102)	S	P
135	/	22	ESOFAGO	A Phase 1/2 Open-Label, Umbrella Platform Design of Investigational Agents With Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer: Master (KEYMAKER-U06)	S	P
181	/	22	GASTRO-ENTERICO	A Randomized, Multicenter, Phase 3 Study of Zanidatamab in Combination with Chemotherapy with or without Tislelizumab in Subjects with HER2-positive Unresectable Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma (GEA)	S	P
144	/	15	T. UROGENITALE (RENE-PROSTATA)	Banca Dati Metastasi Ossee	O	NP

STUDI ATTIVI AL RECLUTAMENTO S.C. OM1

71	/	18	T. UROGENITALE (RENE-PROSTATA)	indagare fattori predittivi di risposta in pazienti affetti da carcinoma renale metastatico (mRCC) trattati con Nivolumab (studio I-RENE)	O	NP
147	/	18	T. UROGENITALE (RENE-PROSTATA)	BIORENE (No profit osservazionale BIOLOGICO prospettico) Studio prospettico traslazionale volto ad indagare fattori prognostici e predittivi di risposta o resistenza ai trattamenti in pazienti affetti da carcinoma renale metastatico (mRCC)	O	NP
107	/	18	T. UROGENITALE (RENE-PROSTATA)	ACACIA (No profit con farmaco) Studio multicentrico, randomizzato, in aperto di fase III volto a valutare l'attività di chemioterapia adiuvante versus osservazione/mitotane dopo chirurgia di prima linea in pazienti affetti da carcinoma corticosurrenale localizzato ad alto rischio di recidiva	S	NP
228	/	19	T. UROGENITALE (RENE-PROSTATA)	Studio osservazionale retrospettivo sulla sicurezza di Nivolumab nei Pazienti con Carcinoma Renale Metastatico ed Insufficienza Renale	O	NP
164	/	18	T. UROGENITALE (RENE-PROSTATA)	Meet-URO 4 - Studio multicentrico randomizzato di fase III: Docetaxel vs ormonoterapia come trattamento di seconda linea in pazienti asintomatici o oligosintomatici con tumore della prostata metastatico, resistente alla castrazione, in progressione dopo terapia con abiraterone o enzalutamide. (Non-Profit)	S	NP
175	/	20	T. UROGENITALE (RENE-PROSTATA)	Osteonecrosi della mandibola in pazienti affetti da carcinoma renale con metastasi ossee. Studio retrospettivo multicentrico (studio REBONE)	O	NP

STUDI ATTIVI AL RECLUTAMENTO S.C. OM1

5	/	21	T. UROGENITALE (RENE-PROSTATA)	AMPLITUDE- A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC).	S	P
135	/	21	T. UROGENITALE (RENE-PROSTATA)	DAROL Darolutamide Observational Study in non-metastatic castration-resistant prostate cancer patients".	O	P
89	/	21	T. UROGENITALE (RENE-PROSTATA)	KATY:Studio Osservazionale prospettico biologico/retrospetivo (raccolta campioni biologici)	O	NP
103	/	21	T. UROGENITALE (RENE-PROSTATA)	An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Belzutifan (MK-6482) and Lenvatinib (MK-7902), or MK-1308A in Combination with Lenvatinib, versus Pembrolizumab and Lenvatinib, as First-line Treatment in Participants with Advanced Clear Cell Renal Cell Carcinoma (ccRCC)	S	P
04	/	22	T. UROGENITALE (RENE-PROSTATA)	A Multicenter, Double-blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma (ccRCC) Post Nephrectomy (MK-6482-022)	S	P
35	/	21	T. UROGENITALE (RENE-PROSTATA)	An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib (MK-7902) vs Cabozantinib for Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1/L1 Therapy	S	P

STUDI ATTIVI AL RECLUTAMENTO S.C. OM1

17	/	18	UROTELIO- TESTICOLO- GERMINALI	THOR- A Phase 3 Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations	S	P
179	/	18	UROTELIO- TESTICOLO- GERMINALI	STUDIO CLINICO DI FASE 3, RANDOMIZZATO, CONTROLLATO CON PRODOTTO DI CONFRONTO PER STUDIARE L'EFFICACIA E LA SICUREZZA DI PEMBROLIZUMAB (MK-3475) IN COMBINAZIONE CON BACILLO DI CALMETTE -GUERIN (BCG) IN SOGGETTI AFFETTI DA TUMORE DELLA VESCICA NON-MUSCOLO INVASIVO AD ALTO RISCHIO (HR NMIBC) CHE E' PERSISTENTE O RICORRENTE DOPO INDUZIONE CON BCG.	S	NP
180	/	18	UROTELIO- TESTICOLO- GERMINALI	Cabozantinib plus durvalumab (Medi 4736) in patients with advanced and chemotherapy-treated bladder carcinoma, of urothelial and non-urothelial histology: an open-label, single-centre, phase 2, single-arm proof-of-concept trial-ARCADIA	S	NP
94	/	19	UROTELIO- TESTICOLO- GERMINALI	Studio Randomizzato di fase III su Pembrolizumab Perioperatorio più Cistectomia versus Cistectomia in pazienti Cisplatino-elegibili affetti da carcinoma della vescica muscolo-invasivo (KEYNOTE-905)"	S	P
3	/	20	UROTELIO- TESTICOLO- GERMINALI	Studio clinico di fase 3, randomizzato, in doppio cieco, controllato con placebo per studiare l'efficacia e la sicurezza di Pembrolizumab (MK-3475) in combinazione con la Chemioradioterapia (CRT) versus la sola Chemioradioterapia in soggetti con tumore alla vescica muscolo-invasivo (MIBC) (KEYNOTE-992)	S	P

STUDI ATTIVI AL RECLUTAMENTO S.C. OM1

45	/	18	POLMONE	Exploiting metformin plus/minus cyclic Fasting Mimicking Diet (FMD) to improve the efficacy of first line chemo-immunotherapy in advanced LKB1-inactive lung adenocarcinoma	O	NP
146	/	15	POLMONE	PROGETTO TIMOMA:CREAZIONE DI UN DATABASE GENETICO E CLINICO PER LO STUDIO DELLE NEOPLASIE EPITELIALI TIMICHE	O	NP
23	/	18	POLMONE	NO-PROFIT_Miglioramento delle strategie di trattamento nei tumori epiteliali del timo: un impegno congiunto del TYME Studio RELEVANT.	S/O	NP
212	/	18	POLMONE	A Phase II, Randomized, Open-label Platform Trial Utilizing a Master Protocol to Study Novel Regimens Versus Standard of Care Treatment in NSCLC Participants	S	P
119	/	19	POLMONE	Uno studio multicentrico randomizzato di fase III che mette a confronto atezolizumab più bevacizumab e la chemioterapia standard rispetto a bevacizumab e la chemioterapia standard come trattamento di prima linea per il mesotelioma pleurico maligno di stadio avanzato. no profit	S	NP
196	/	19	POLMONE	TRIDENT -1A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients with Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)	S	P

STUDI ATTIVI AL RECLUTAMENTO S.C. OM1

235	/	19	POLMONE	A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody, in Subjects with Advanced Non-Small Cell Lung Cancer	S	p
237	/	19	POLMONE	Studio randomizzato, in aperto, di fase 3, di SAR408701 rispetto a Docetaxel in pazienti con neoplasia polmonare metastatica già trattata non a piccole cellule e a cellule non squamose con tumori positivi a CEACAM5	S	P
37	/	18	POLMONE	MILES 5 : A randomized phase 2 study comparing immunotherapy with chemotherapy in the treatment of elderly patients with advanced NSCLC.	S	NP
182	/	20	POLMONE	BLU 667 : A Randomized, Open-Label, Phase 3 Study of Pralsetinib versus Standard of Care for First Line Treatment of RET fusion-positive, Metastatic Non-Small Cell Lung Cancer	S	P
60	/	21	POLMONE	A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Pembrolizumab (MK-3475) in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab with or without Olaparib (MK-7339), Compared to Concurrent Chemoradiation Therapy Alone in Participants with Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC)	S	p

STUDI ATTIVI AL RECLUTAMENTO S.C. OM1

291	/	20	POLMONE	A Phase 3 Study of Pembrolizumab (MK-3475) in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab with or without Olaparib vs Concurrent Chemoradiation Therapy Followed by Durvalumab in Participants with Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer (NSCLC)	S	P
59	/	21	POLMONE	BRIDGE trial: Phase II trial of durvalumaB and chemotheRapy Induction followed by Durvalumab and radiotherapy in larGe volumE stage III NSCLC	S	NP
175	/	21	POLMONE	Studio di fase 2, non randomizzato, in aperto, multicoorte, multicentrico per valutare il beneficio clinico di SAR444245 (THOR-707) in combinazione con altre terapie antitumorali per il trattamento di pazienti con carcinoma polmonare o mesotelioma pleurico	S	P
153	/	21	POLMONE	LUNG- GSK213410 "A randomized, open-label phase 2/3 study comparing Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel alone in participants with advanced Nonsmall Cell Lung Cancer who have progressed on prior anti-PD-(L)1 therapy and chemotherapy (COSTAR lung)" – Protocollo 213410"	S	P
197	/	21	POLMONE	A RANDOMIZED PHASE 3 STUDY OF MRTX849 VERSUS DOCETAXEL IN PATIENTS WITH PREVIOUSLY TREATED NON-SMALL CELL LUNG CANCER WITH KRAS G12C MUTATION	S	P

STUDI ATTIVI AL RECLUTAMENTO S.C. OM1

23	/	22	POLMONE	A Phase 3, Randomized, Double-Blind Study of MK-7684A in Combination with Etoposide and Platinum Followed by MK-7684A vs Atezolizumab in Combination with Etoposide and Platinum Followed by Atezolizumab for the First-Line Treatment of Participants with Extensive-Stage Small Cell Lung Cancer	S	P
22	/	15	POLMONE	APOLLO	O	NP
147	/	22	POLMONE	Progetto europeo per l'implementazione di cure mediche personalizzate basate sull'intelligenza artificiale (AI) nei pazienti con tumore al polmone_ I3LUNG	O	NP
128	/	22	POLMONE	APOLLO 11, CONSORZIO DI CENTRI COINVOLTI NELLA CURA DI PAZIENTI CON TUMORE POLMONARE TRATTATI CON TERAPIE INNOVATIVE: INTEGRAZIONE DI DATI REAL WORLD E RICERCA TRASLAZIONALE	O	NP
196	/	22	POLMONE	An Open-label, Multicenter, Phase 3 Randomized, Active-Comparator-Controlled Clinical Study of Pembrolizumab (MK-3475) in Combination With Sacituzumab Govitecan Versus MK-3475 Monotherapy as First-line Treatment in Participants With PD L1 TPS Greater than or Equal to 50% Metastatic Non-small Cell Lung Cancer (KEYNOTE D46/EVOKE-03)	S	P

STUDI ATTIVI AL RECLUTAMENTO S.C. OM1

88	/	19	POLMONE	Phase II, Single Arm Study Assessing the Efficacy of Osimertinib in Combination with Savolitinib in Patients with EGFRm+ and MET+, Locally Advanced or Metastatic Non-Small Cell Lung Cancer who have Progressed Following Treatment with Osimertinib (The SAVANNAH Study)- profit	S	P
65	/	22	POLMONE	Open-label Phase 3 Study of MK-7684A (Coformulation of Vibostolimab with Pembrolizumab) in Combination with Concurrent Chemoradiotherapy followed by MK-7684A Versus Concurrent Chemoradiotherapy followed by Durvalumab in Participants with Unresectable, Locally Advanced, Stage III NSCLC	S	P
228	/	20	MELANOMA	Study of Durvalumab for the Treatment of Stage II-III NSCLC Patients	S	P
186	/	20	MELANOMA	with Minimal Residual Disease Following Surgery and Curative Intent	S	P
71	/	21	MELANOMA	Studio osservazionale, retrospettivo-prospettivo volto all'individuazione di nuovi fattori prognostici e predittivi in pazienti affetti da melanoma sottoposti a terapia antitumorale	O	NP

STUDI ATTIVI AL RECLUTAMENTO S.C. OM1

262	/	20	MELANOMA	Studio di fase II, randomizzato, non-comparativo, sulla terapia neoadiuvante più adiuvante con combinazione o sequenza di vemurafenib, cobimetinib e atezolizumab in pazienti con melanoma ad alto rischio, asportabile chirurgicamente con mutazione BRAF o wild type	S	NP
57	/	21	MELANOMA	A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants With Melanoma (KEYMAKER-U02): Substudy 02D	S	P
62	/	22	MELANOMA	A Phase I, open-label, dose escalation study of oral LGK974 in patients with malignancies dependent on Wnt ligands	S	P
243	/	21	MELANOMA	A Phase 3, Randomized, Double-blind Study of Encorafenib and Binimetinib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab in Participants with BRAF V600E/K Mutation-Positive Metastatic or unresectable locally advanced Melanoma	S	P
36	/	22	MELANOMA	A Phase 2, Open-label, Multicenter, Cohort Study of Nivolumab (ALKS 4230) Monotherapy Administered Subcutaneously in Patients With Advanced Cutaneous Melanoma or Intravenously in Patients With Advanced Mucosal Melanoma Who Have Previously Received Anti-PD-[L]1 Therapy - ARTISTRY-6	S	P

STUDI ATTIVI AL RECLUTAMENTO S.C. OM1

15	/	22	MELANOMA	Registro Clinico Nazionale sul Melanoma II	O	NP
116	/	22	MELANOMA	Adjuvant encorafenib & binimetinib vs. placebo in fully resected stage IIB/C BRAF V600E/K mutated melanoma: a randomized triple-blind phase III study in collaboration with the EORTC Melanoma Group	S	P
155	/	18	TUMORI SOLIDI	"Studio di fase 1 con aumento progressivo della dose e ampliamento delle coorti, per la valutazione di TSR-042, un anticorpo monoclonale anti-PD-1, in pazienti affetti da tumori solidi in stadio avanzato" - N. protocollo: 4010-01-001	S	P
63	/	18	TUMORI SOLIDI	Studio di fase 1/2 su LOXO-292 Orale in pazienti con tumori solidi avanzati, che include tumori solidi positivi con fusione di RET, carcinoma midollare della tiroide e altri tumori con attivazione RET (LIBRETTO-001).	S	P
89	/	19	TUMORI SOLIDI	Studio multicentrico, di fase 1/2, in aperto per valutare la sicurezza e l'efficacia di KY1044 come agente singolo e in combinazione con anti-PD-L1 (atezolizumab) in pazienti adulti con tumori maligni selezionati in stadio avanzato	S	P
169	/	19	TUMORI SOLIDI	A Phase I Dose Escalation Study of NMS-03305293 in Adult Patients with Selected Advanced/Metastatic Solid Tumors	S	P

STUDI ATTIVI AL RECLUTAMENTO S.C. OM1

36	/	20	TUMORI SOLIDI	Studio di Fase I/Ib, in aperto, multicentrico, con KAZ954 in monoterapia e in associazione a Spartalizumab, NZV930 e NIR178 in pazienti con tumori solidi in stadio avanzato	S	P
180	/	20	TUMORI SOLIDI	Phase I/II study on safety and efficacy of NMS-01940153E in adult patients with unresectable hepatocellular carcinoma (HCC) previously treated with systemic therapy	S	P
56	/	21	TUMORI SOLIDI	A phase Ib/II open-label, multi-center dose escalation study of JDQ443 in patients with advanced solid tumors harboring the KRAS G12C mutation	S	P
193	/	21	TUMORI SOLIDI	A PHASE I/Ib GLOBAL, MULTICENTER, OPEN-LABEL UMBRELLA STUDY EVALUATING THE SAFETY AND EFFICACY OF TARGETED THERAPIES IN SUBPOPULATIONS OF PATIENTS WITH METASTATIC COLORECTAL CANCER	S	P

STUDI ATTIVI AL RECLUTAMENTO S.C. OM1

191	/	21	TUMORI SOLIDI	Phase Ib Multicenter, Open-label Dose-escalation Study to Evaluate the Safety and Tolerability of Trastuzumab Deruxtecan (T-DXd) and Durvalumab in Combination with Cisplatin, Carboplatin or Pemetrexed in First-line Treatment of Patients with Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) and Human Epidermal Growth Factor Receptor2 Overexpression (HER2+)(DESTINY-Lung03)	S	P
222	/	21	TUMORI SOLIDI	A Phase I/Ib, open-label, multi-center study of DFF332 as a single agent and in combination with Everolimus or IO agents in patients with advanced/relapsed ccRCC and other malignancies with HIF2 α stabilizing mutations	S	P
5	/	22	TUMORI SOLIDI	A Phase 1/2 Study of BMS-986340 as Monotherapy and in Combination with Nivolumab in Participants with Advanced Solid Tumors	S	P
60	/	22	TUMORI SOLIDI	A SINGLE-ARM, OPEN-LABEL, MULTICENTER PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TALETRECTINIB IN PATIENTS WITH ADVANCED OR METASTATIC ROS1 POSITIVE NSCLC AND OTHER SOLID TUMORS	S	P

STUDI ATTIVI AL RECLUTAMENTO S.C. OM1

241	/	21	TUMORI SOLIDI	“An open-label, Phase 1b, dose escalation and expansion study to evaluate the safety, tolerability, maximum tolerated or administered dose, pharmacokinetics, pharmacodynamics and efficacy of the Aryl Hydrocarbon Receptor inhibitor (AhRi) BAY 2416964 in combination with pembrolizumab in participants with advanced solid tumors”	S	P
21	/	22	TUMORI SOLIDI	A Phase 1/2 Study of PBI-200 in Subjects with NTRK-Fusion-Positive Advanced or Metastatic Solid Tumors	S	P
61	/	21	TUMORI SOLIDI	Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects with Non-Small Cell Lung Cancer with c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors	S	P
66	/	21	TUMORI SOLIDI	TUMOR-AGNOSTIC PRECISION IMMUNO-ONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU(TAPISTRY)PHASE IIPLATFORM TRIAL	S	P

STUDI ATTIVI AL RECLUTAMENTO S.C. OM1

192	/	21	TUMORI SOLIDI	Basket of Baskets: A Modular, Open-label, Phase II, Multicentre Study To Evaluate Targeted Agents in Molecularly Selected Populations With Advanced Solid Tumours.	S	NP
200	/	20	C.MAMMARIO	A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF GDC-0077 PLUS PALBOCICLIB AND FULVESTRANT VERSUS PLACEBO PLUS PALBOCICLIB AND FULVESTRANT IN PATIENTS WITH PIK3CA-MUTANT, HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER	S	P
196	/	20	C.MAMMARIO	A Master Protocol Empowering Mechanobiology Translational Research in Breast Cancer	O	NP
127	/	21	C.MAMMARIO	A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF ADJUVANT ATEZOLIZUMAB OR PLACEBO AND TRASTUZUMAB EMTANSINE FOR HER2-POSITIVE BREAST CANCER AT HIGH RISK OF RECURRENCE FOLLOWING PREOPERATIVE THERAPY	S	P

STUDI ATTIVI AL RECLUTAMENTO S.C. OM1

138	/	21	C.MAMMARIO	Observational study of effectiveness and safety of trastuzumab emtansine (T-DM1) in HER2-positive breast cancer patients with residual invasive disease following neoadjuvant chemotherapy and anti-HER2 target therapy”	O	NP
221	/	21	C.MAMMARIO	EPIK-B5: Studio di Fase III, randomizzato, in doppio cieco, controllato versus placebo, conalpelisib (BYL719) in associazione a fulvestrant negli uomini e nelle donne in post-menopausa con carcinoma mammario in stadio avanzato HR-positivo, HER2-negativo con mutazione PIK3CA, che ha manifestato progressione durante o dopo inibitore dell'aromatasi e inibitore di CDK4/6	S	P
108	/	22	C.MAMMARIO	NONINTERVENTIONAL, MULTICENTRE, PROSPECTIVE, COHORT STUDY ASSESSING THE QUALITY OF LIFE AND HORMONAL LEVELS IN PREMENOPAUSAL PATIENTS WITH HORMONE RECEPTOR-POSITIVE AND HER2-NEGATIVE EARLY BREAST CANCER IN ITALY – ROSE STUDY NONINTERVENTIONAL, MULTICENTRE, PROSPECTIVE, COHORT STUDY ASSESSING THE QUALITY OF LIFE AND HORMONAL LEVELS IN PREMENOPAUSAL PATIENTS WITH HORMONE RECEPTOR-POSITIVE AND HER2-NEGATIVE EARLY BREAST CANCER IN ITALY – ROSE STUDY	O	NP

STUDI ATTIVI AL RECLUTAMENTO S.C. OM1

139	/	22	C.MAMMARIO	A MULTI-COUNTRY OBSERVATIONAL RETROSPECTIVE STUDY TO EVALUATE THE PREVALENCE OF PD-L1 AND ITS ROLE IN PATIENTS WITH TNBC TREATED WITH SYSTEMIC THERAPY (VANESSA)	O	P
245	/	21	TUMORI SOLIDI	Immune checkpoint inhibitors and Carbon iON radiotherapy In solid Cancers with stable disease (ICONIC)	S	NP
31	/	19	DIETA	Efficacy of metfOrmin in PrevenTing glucocorticoid-induced diabetes in Melanoma, breAst or Lung cancer patients with brain metastases: the phase II OPTIMAL study	S	NP
157		17	DIETA	Impact of Dietary Intervention on tumor immunity: The DigesT trial	S	NP